Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR)
2016; Elsevier BV; Volume: 27; Issue: 12 Linguagem: Inglês
10.1093/annonc/mdw418
ISSN1569-8041
AutoresJalid Sehouli, Radoslav Chekerov, Alexander Reinthaller, Rolf Richter, Antonio González‐Martín, Philipp Harter, Hannah Woopen, Edgar Petru, Lars Hanker, E. Keil, Pauline Wimberger, Peter Klare, Christian Kurzeder, Felix Hilpert, Antje Belau, Alain G. Zeimet, I. Bover-Barcelo, Ulrich Canzler, Sven� Mahner, Werner Meier,
Tópico(s)Testicular diseases and treatments
Referência(s)